Main Article Content

Audit of efficacy of CoartemTM to clear plasmodium falciparum malaria parasitaemia at single forty-two day follow-up


CH Vaughan-Williams
C La Cock
BLF Bredenkamp

Abstract

Background; A study, which included a follow-up study, was undertaken to assess the efficacy of CoartemTM tablets (20 mg artemether and 120 mg lumefantrine – Novartis South Africa (Pty) Ltd) to clear plasmodium falciparum malaria parasitaemia at a single 42-day follow-up, with 42 days being chosen in order to detect early emergence of resistance. The study was done at Ndumo Clinic and Mosvold Hospital in the Ingwavuma District of KwaZulu-Natal, South Africa in January/February 2002.


Method: The study included 37 patients presenting to Ndumo Clinic and two presenting to Mosvold Hospital with uncomplicated malaria diagnosed by symptoms and a positive immunochromographic test (ICT) for plasmodium falciparum. The main outcome measures were done using a Trophozoite count on thick film and polymerase chain reaction parasite analysis of blood spot at day 42.


Results: Only 31 of the 37 recruited patients were confirmed to be suffering from malaria by polymerase chain reaction (PCR). Of the 31, 24 returned for follow-up. One patient had parasitaemia at day 33, but tested negative at day 42 after re-treatment with Coartem™. It was not determined whether this patient was suffering from a recrudescence or re-infection of falciparum malaria. All the other returning patients tested negative for falciparum malaria on blood film and PCR examination.


Conclusions : CoartemTM still appears to be an effective treatment for falciparum malaria. Regular assessment of its efficacy is desirable.


For full text, click here:SA Family Pract 2004;46(6): 21-24

Journal Identifiers


eISSN: 2078-6204
print ISSN: 2078-6190